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29-year-old Hispanic woman presented to the clinic with complaints of abdominal pain, nausea, fatigue, and constipation.
Laboratory tests indicated the presence of iron deficiency anemia and transaminitis. Imaging evaluation revealed marked
hepatomegaly withmultiple hepaticmetastases and pelvic lymphadenopathy. Biopsy of the hepatic lesions showed adenocarcinoma
positive for pan-cytokeratin, CMA5.2, villin, and CDX2. She was positive for tumor markers CA 19-9, CA-125, and CEA. Upon
further evaluation, she was found to have colorectal cancer positive for KRAS and BRAF mutations. Unfortunately, her disease
progressed rapidly and she expired within 3 months from the time of her first diagnosis. KRAS and BRAF mutations are rare
enough to be considered virtually mutually exclusive but coexistent mutations appear to be a distinct molecular and clinical subset
with aggressive course of illness, which is in dire need of new treatment strategies. Panitumumab and Cetuximab are approved for
patients with wild type KRAS CRC. Vemurafenib is a potent inhibitor of the kinase domain in mutant BRAF and its use in BRAF
mutated colon cancer remains to be well established. Our report highlights the need to obtain tissue samples from these patients
for analysis and to evaluate the benefit of Vemurafenib in colorectal cancers.
1. Introduction
Colorectal cancer is the third most commonly diagnosed
cancer and leading cause of cancer death in men and
women. In 2017, 1688780 new cancer cases and 600920
cancer deaths are projected to occur in United States [1].
Activating mutations in human Kirsten rat sarcoma viral
oncogene (KRAS) are detected in approximately 40 percent
ofmetastatic colorectal cancer (mCRC).Mutations inmurine
sarcoma viral oncogene homolog B1 (BRAF) are found in 5 to
10 percent of mCRC [2].
The RAS-RAF-MEK-ERK signaling pathway (MAPK
pathway) is a classical intracellular pathway that plays a
crucial role in homeostasis of normal cell turnover, cellular
proliferation, differentiation, survival, and apoptosis. The
activation of the epidermal growth factor receptor (EGFR)
signaling cascade is a well-known pathway that can lead to
colon cancer.Mutationwithin theKRAS exon 2 and extended
RAS (i.e., KRAS exons 3 and 4 and NRAS exons 2, 3, and 4)
oncogene located downstream to EGFR within this pathway
leads to its activation, even if the EGFR is blocked [3–5]. Con-
sequently, tumors with mutated KRAS and probably BRAF
are resistant to anti-EGFR therapy [6]. CRYSTAL, PEAK, and
PRIME are few of themost important randomized controlled
trials that have demonstrated that addition of anti-EGFR
drugs to chemotherapy in patients with KRAS mutations
has detrimental outcomes [7–9]. Here, we report a case of
metastatic colon cancer with coexistent KRAS and BRAF
mutations. Concomitant KRAS and BRAF mutant CRCs are
rare, occurring in less than 0.001% of cases [10].
2. Case Presentation
A 29-year-old noncigarette smoking Hispanic woman with
no significant medical, family, and surgical history presented
to the clinic with complaints of abdominal pain, nausea,
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fatigue, constipation, and subjective fevers at nights for 3
weeks. Vital signs were stable and physical examwas remark-
able for mild tenderness in left lower quadrant. Laboratory
tests indicated the presence of microcytic hypochromic iron
deficiency anemia and mild elevation in her liver function
enzymes. Hemoglobin was 7.8 and AST/ALT/ALP were 92,
34, and 144. Computerized tomography (CT) scan showed a
large pelvicmass (11 cm)with uterinemass (fistulous commu-
nication to colon), retroperitoneal, pelvic lymphadenopathy,
and widespread hepatic metastasis. The fevers, abdominal
pain, and constipation were attributed to her malignancy and
the uterine mass was thought to be a fibroid.
Follow-up positron emission tomography scan (PET
scan) was obtained to look for primary malignancy and it
showed abdominal, pelvic lymphadenopathy and innumer-
able necrotic lesions in the liver concerning for metastasis
and a pelvic mass. As her imaging raised suspicions for
malignancy, she underwent liver biopsy and flexible sigmoi-
doscopy. Biopsy of the hepatic lesions showed adenocarci-
noma and immunohistochemical staining was positive for
pan-cytokeratin, CMA5.2, villin, and CDX2 and negative for
PAX- 8, ER, PAX-5, CK7, CK20, Hep-par1, and vimentin.
FISH (fluorescent in situ hybridization) for high risk HPV
was found to be negative. Immunohistochemical stainingwas
suggestive of GI (gastrointestinal) primary or a carcinoma
with enteric differentiation. Tumor markers were as follows:
CA19-9 = 981, CA-125 = 205, and CEA = 284.3. Flexible
sigmoidoscopy showed circumferential necrotic mass which
was present 11 cm from the anal verge extending 7-8 cm
distally. Mass was very friable with bleeding noted even with
minor scope friction. Biopsies were obtained and they were
sent for extended RAS mutation analysis as colorectal cancer
was thought to be primary based on the workup obtained
so far. Biopsies were also tested for mutations and they were
positive for KRAS mutation (C 35 G>A/p. G12D) and BRAF
mutation exon 15 codon600 atV600E (GAG),V600D (GAT),
or V600K (AAG). Her pathologic staging was pT4N1M1.
She was not a good candidate for surgical management,
so decision to start chemotherapy was made. As she was
found to be positive for both KRAS and BRAF, she was not
considered a candidate for anti-EGFR treatment. Anti-VEGF
treatment (Bevacizumab) could not be considered in her
case as she had an active infectious fistulous communication
between a uterine fibroid and the bowel wall. FOLFOX
therapy was administered for 2 cycles and she tolerated it
well. Further cycles of chemotherapy were not administered
as she was deemed unresponsive to treatment based on
visualization of progressive lesions and poor performance
status. Unfortunately, her disease progressed rapidly and she
expired within 3 months from the time of her first diagnosis.
3. Discussion
This rare case of metastatic colorectal cancer with con-
comitant KRAS and BRAF mutations had several unusual
features including young age of presentation with no risk
factors, harboring concomitant KRAS and BRAF, and rapid
progression of disease to death within 3 months of the onset
of disease. This case report emphasizes the importance of
obtaining baseline testing of KRAS and BRAFmutations as it
appears that the patients who have coexistent mutations tend
to have aggressive course of illness as evident in this patient
as she survived only 3 months from the time of diagnosis.
Possible mechanism of having coexistent KRAS and BRAF
mutation is unknown as its frequency is very low and it is not
clear whether or not these tumors have a different biology
and natural history than KRAS or BRAF mutant tumors or
which of the twomutations is the dominant oncogene driving
tumor proliferation [8]. A study by Seth et al. has shown
that coexistent KRAS and BRAF tumor mutations have been
observed in 1 cell line of the 24 cell lines that have been studied
but information on clinical impact was not available. Also we
do not know if KRAS or BRAF or both are driver mutations
[11]. Another possible mechanism to be considered is the
presence of biclonal population of tumor cells, with one clone
harboring KRAS mutation and the other clone harboring
BRAF mutation.
Epidermal growth factor receptor (EGFR) targeted anti-
bodies were approved for clinical use in patients with
metastatic CRC. Several retrospective analyses of prospective
clinical trials in CRC patients receiving anti-EGFR antibody
treatment have shown that patients with mutated KRAS did
not benefit from anti-EGFR therapy. The KRAS data has
changed the paradigm of anti-EGFR antibody treatment in
CRC. CRYSTAL and PRIME are two most important phase
III randomized controlled trials that have demonstrated that
addition of anti-EGFR drugs to chemotherapy has detrimen-
tal outcomes in KRASmutant mCRC. CRYSTAL trial studied
FOLFIRI +/− Cetuximab in mCRC. The median OS (overall
survival) with FOLFIRI +Cetuximabwas 24.9months inwild
type KRAS and 17.5 months in mutant KRAS. The PRIME
study (FOLFOX4 +/− Panitumumab) showed median OS of
23.9 months in wild type KRAS and 15.5 in mutant KRAS.
PEAK study is the first randomized trial which studied the
effect of Panitumumab (anti-EGFR antibody) + mFOLFOX6
compared to Bevacizumab (anti-VEGF antibody) + mFOL-
FOX6 for first-line treatment of wild type KRAS metastatic
colon cancer. PFS was similar but OS was statistically and
clinically improved in Panitumumab arm (median OS 41.3
months) when compared to Bevacizumab arm (median OS
28.9 months). In the prospective secondary analysis of PEAK
study, patients with extended RAS wild type were found to
have PFS of 13 months in Panitumumab arm and 9.5 months
in Bevacizumab arm [7].
The impact of BRAF has also been retrospectively eval-
uated on tissue from completed prospective trials. MRC
(Medical Research Council) COIN trail was the largest trial
that studied the effect of anti-EGFR treatment (Cetuximab) to
chemotherapy regimen of Oxaliplatin and fluoropyrimidine
in mCRC; and the effect was further analyzed for KRAS,
NRAS, and BRAF mutations. This was the first trial that
showed that addition of anti-EGFR drugs to chemotherapy
in BRAFmutant mCRC had worse outcomes. Median overall
survival was shorter in BRAFmutant CRC (8.8 months) than
in thosewithBRAF andKRASwild type tumors (17.5months)
[12].
Vemurafenib is FDAapproved to be used inBRAFmutant
melanoma. Single agent Vemurafenib which is an inhibitor
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of BRAF V600E has been tested in BRAF mutant CRC but
failed to show antitumor activity [13]. When Vemurafenib
blocks BRAF activity and cuts off signaling within theMAPK
pathway, this kicks on a feedback mechanism leading to
upregulation of upstreamEGFR, once again driving signaling
through the MAPK pathway upon which these tumors are so
dependent. To prevent this molecular escape route, the addi-
tion of EGFR inhibitor Cetuximabwas tested in a clinical trial
conducted by Southwest Oncology group (NCT02164916).
99 patients with BRAFV600E-mutated and RAS wild type
mCRC received irinotecan and Cetuximab +/−Vemurafenib.
The addition of Vemurafenib to irinotecan and Cetuximab
doubled the median PFS from 2.0 months to 4.4 months. Of
note, none of these patients were KRAS mutant. So we still
do not know the optimal management for metastatic CRC
harboring concomitant KRAS + BRAF mutations.
4. Conclusions
Many centers test for KRAS mutation. If it is found to be
KRASmutant, then BRAF testing is not performed.However,
if KRAS is wild type, then BRAF testing is obtained in
a sequential manner. On the basis of this case experience
and review of literature, we conclude that mCRC harboring
concomitant KRAS+BRAFmutations is a distinct and highly
aggressive subset which is in dire need of new therapeutic
strategies. Hence, baseline testing of KRAS, extended RAS,
and BRAF mutations needs to be obtained as a standard of
care in the clinical management of mCRC patients instead of
sequential testing approach. We are currently conducting a
retrospective chart review study to assess the incidence and
biology of coexisting mutations in mCRC at University of
Kansas Medical Center. In addition, we will evaluate coexist-
ing RAS (KRAS and extended RAS) and BRAFmutations as a
prognostic marker and as a tool to predict a more aggressive
biological phenotype of metastatic colon cancer. Metastatic
CRC with concomitant RAS + BRAF mutations should be
assigned to a separate arm in clinical trials to evaluate the role
of novel therapeutics for this deadly disease.
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